newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research clinical trial-- Raised $8.8 million in gross proceeds from a private placement and warrant